- Current report filing (8-K)
18 Octubre 2010 - 1:00PM
Edgar (US Regulatory)
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 14,
2010
MABCURE INC.
(Exact name
of registrant as specified in its charter)
Nevada
(State or other jurisdiction of
incorporation)
333-141131
(Commission File Number)
20-4907813
(IRS Employer Identification
No.)
De Schiervellaan 3/B1
Hasselt, Belgium
3500
(Address of principal executive offices and Zip Code)
+32 (487) 425303
(Registrant's telephone
number, including area code)
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
Item
5.02
Departure of Directors
or Principal Officers; Election of Directors; Appointment of Principal
Officers
On October 14, 2010, the Board of
Directors of the Registrant expanded the number of members serving on the Board
of Directors from four to five and approved the appointment of Dr. Elisha Orr to
its Board of Directors.
Dr. Orr, age 66, MabCures
Executive Vice-President and Chief Scientific Officer since July 7, 2008, is the
developer of the MabCure technology and its novel MAbs. He has been serving as a
senior research scientist in the Department of Genetics at the University of
Leicester, United Kingdom, for the past thirty years. He has received awards
from several institutions, among them the Wellcome Trust Personal Chair award
for five years in 1987, the Royal Society (UK) award for a visiting
professorship in Israel in 1994, a European Union award for a visiting
professorship in Israel in 1998, and several long and short term awards from the
European Molecular Biology Organization (EMBO). Dr. Orr received his Doctorate
degree in Microbiology & Molecular Biology from Hadassah Medical School,
Jerusalem. He completed his post-doctorate training at the Department of
Genetics at the University of Leicester.
Dr. Orr will not receive any
additional compensation for serving on the Board of Directors of the Registrant.
The Registrant compensates Dr. Orr for the services he provides to the
Registrant pursuant to the terms of a management services agreement, which
agreement is described in the Registrants Annual Report on Form 10-K filed with
the SEC on March 24, 2010.
There are no family relationships
between any of our Directors and/or executive officers.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
|
MABCURE INC.
|
|
(Registrant)
|
|
|
|
|
|
|
|
By:
/s/ Dr. Amnon Gonenne
|
|
Dr. Amnon Gonenne
|
|
President and Chief
Executive Officer
|
Date: October 18, 2010
MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024